Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.
Emsere, headquartered in Leiden in the Netherlands, is a medical equipment rental specialist providing clinical trial equipment and logistics solutions to pharmaceutical companies and contract research organisations (CROs) globally.
Founded in 1996, Emsere manages over 13,000 pieces of equipment and delivers to more than 100 countries, serving six of the top 10 global pharmaceutical companies and seven of the top 10 CROs. Its portfolio includes centrifuges, imaging devices, cardiovascular and respiratory monitors, and cardio-pulmonary exercise testing equipment.
The company operates in the growing clinical trial equipment rental market, addressing demand for outsourced, complex, and regulatory-compliant solutions delivered at scale. Emsere's services allow clients to focus on scientific and clinical execution while avoiding capital expenditure and logistical coordination.
Antin's investment marks the eighth for its EUR2.2bn Mid Cap Fund I and continues its strategy of scaling health and medical infrastructure companies in Europe and North America. Emsere's CEO Patrice Gerard and senior management will co-invest alongside Antin.
The transaction is expected to close in the first quarter of 2026.
Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device
bioMérieux files FDA application for rapid vaginitis diagnostic panel
Racura Oncology doses first patient in Phase 1 lung cancer trial
EU approves Cenrifki for secondary progressive multiple sclerosis without relapses
Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes
Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Airiver Medical treats first chronic rhinosinusitis patient in Drug Coated Balloon clinical study
Precigen and the RRPF recognise International RRP Awareness Day
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio